Open Nav

Phoenix PharmaLabs, Inc.

  • Bill Crossman, Phoenix PharmaLabs, Inc.

Introduction to Investors

  • Date:Wednesday, October 17
  • Time:10:15 AM - 10:30 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Phoenix PharmaLabs (PPL) is a preclinical drug discovery company focused on development of new potent, non-addictive treatments for pain and addiction therapy. PPL has developed a novel opioid molecule, PPL-103, that is a potent analgesic (10x stronger than morphine), but is non-addicting, does not produce withdrawal and does not cause death from overdose (even at 350x dose) or constipation (even at 100x dose). Unlike other opioids that aggressively stimulate the mu receptor (which produces euphoria), PPL-103 binds strongly to all three opioid receptors (mu, kappa and delta) - and just partially stimulates all of those receptors with very little stimulation of mu. PPL-103 has clearly demonstrated in various animal studies that it does not produce euphoria (or dysphoria). Research has shown that there is a very high correlation between these studies and human studies that measure the potential for abuse and addiction.
  • Company
  • Company HQ City:Woods Cross
  • Company HQ Country:United States
  • Company HQ State:Utah                              
  • CEO/Top Company Official:William Crossman
  • Year Founded:2002
  • Main Therapeutic Focus:Pain Management
  • Lead Product in Development :PPL-103
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Additional Information/Comments:PPL-103 has demonstrated in non-human primates (NHP) that it does not precipitate withdrawal. Consequently, in addition to pain relief it also offers very promising use for addiction therapy as a preferred substitute for methadone, buprenorphine and Suboxone, since those drugs are, in and of themselves, addicting opiates that addicts typically have to remain on for life. PPL-103 has been substantially de-risked in animals relative to problems that are likely to occur with opioids. A vast amount of opioid testing data is available concerning the transition of effects of pure opioid compounds from animals to humans. The predictive validity from animals to humans is very high, and thus there is a high level of confidence that this compound will be safe, effective and beneficial for humans.
  • Size of Last Investment Round:$3 million
  • Total Amount Raised to Date, In All Rounds:$5 million
Bill Crossman
Phoenix PharmaLabs, Inc.